Home / Recalls / Athenex Pharma Solutions, LLC / D-0712-2022

D-0712-2022 Class II Terminated

Recalled by Athenex Pharma Solutions, LLC — Clarence, NY

FDA drug recall D-0712-2022 was initiated by Athenex Pharma Solutions, LLC on March 14, 2022 and is designated Class II. Reason for recall: Defective container The recall status is terminated (terminated August 4, 2022). Affected quantity: N/A.

Recall Details

Product Type
Drugs
Report Date
March 30, 2022
Initiation Date
March 14, 2022
Termination Date
August 4, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

Epinephrine Injection 8 mg per 250 mL in 0.9% Sodium Chloride, 8mg, 250 mL excel bag, Rx only, Athenex Pharma Solutions, LLC, Clarence, NY, 14031, NDC 76154-814-15

Reason for Recall

Defective container

Distribution Pattern

USA nationwide.

Code Information

Lot #: F2101780, F2101781, Exp 6/21/22

Other recalls by Athenex Pharma Solutions, LLC

  • D-0711-2022 Class II — Phenylephrine HCl Injection in 0.9% Sodium Chloride, 20 mg, 250 mL excel bag, Rx (March 14, 2022)
  • D-0709-2022 Class II — Phenylephrine HCl Injection 40 mg per 250 mL in 0.9% Sodium Chloride, 40 mg, 250 (March 14, 2022)
  • D-0706-2022 Class II — Norepinephrine Bitartrate Injection 4mg per 250 mL in 0.9% Sodium Chloride, 4 mg (March 14, 2022)
  • D-0710-2022 Class II — Phenylephrine HCl Injection 50 mg per 250 mL in 0.9% Sodium Chloride, 50 mg, 250 (March 14, 2022)
  • D-0708-2022 Class II — Norepinephrine Bitartrate Injection 8 mg per 250 mL in 0.9% Sodium Chloride, 8 m (March 14, 2022)
  • D-0707-2022 Class II — Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0.9% Sodium Chlori (March 14, 2022)

FDA data resources